Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

National Health Research Institutes, Taiwan: Clinical Trials & FDA Approval Profile

National Health Research Institutes, Taiwan (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (4 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)15.8%
Median Closed Enrollment vs National (145 pts)49 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Health Research Institutes, Taiwan
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)8 (4)
Completed vs Stopped Early7 / 3 (15.8%)
Median Closed Actual Enrollment49 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Health Research Institutes, Taiwan
Hospital Research SiteLocationShared Protocols
Taipei Veterans General HospitalTaipei13
China Medical University HospitalTaichung12
National Cheng Kung University HospitalTainan12

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by National Health Research Institutes, Taiwan
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06981637Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease AfterPhase IIRECRUITING
NCT05170438Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based TreatmentPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the National Health Research Institutes, Taiwan Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI